BR112021018036A2 - Métodos de tratamento de acidemias orgânicas - Google Patents
Métodos de tratamento de acidemias orgânicasInfo
- Publication number
- BR112021018036A2 BR112021018036A2 BR112021018036A BR112021018036A BR112021018036A2 BR 112021018036 A2 BR112021018036 A2 BR 112021018036A2 BR 112021018036 A BR112021018036 A BR 112021018036A BR 112021018036 A BR112021018036 A BR 112021018036A BR 112021018036 A2 BR112021018036 A2 BR 112021018036A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment methods
- organic acidemia
- coa
- methods
- treating organic
- Prior art date
Links
- 201000008152 organic acidemia Diseases 0.000 title abstract 3
- UYVZIWWBJMYRCD-ZMHDXICWSA-N isovaleryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(C)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 UYVZIWWBJMYRCD-ZMHDXICWSA-N 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- MZFOKIKEPGUZEN-FBMOWMAESA-N methylmalonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C(C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MZFOKIKEPGUZEN-FBMOWMAESA-N 0.000 abstract 1
- QAQREVBBADEHPA-IEXPHMLFSA-N propionyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 QAQREVBBADEHPA-IEXPHMLFSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962818372P | 2019-03-14 | 2019-03-14 | |
| PCT/US2020/022760 WO2020186216A1 (en) | 2019-03-14 | 2020-03-13 | Methods of treating organic acidemias |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021018036A2 true BR112021018036A2 (pt) | 2021-11-23 |
Family
ID=72426817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021018036A BR112021018036A2 (pt) | 2019-03-14 | 2020-03-13 | Métodos de tratamento de acidemias orgânicas |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220142955A1 (https=) |
| EP (1) | EP3937922A4 (https=) |
| JP (1) | JP2022525339A (https=) |
| KR (1) | KR20210139274A (https=) |
| CN (1) | CN113557014A (https=) |
| AU (1) | AU2020236023A1 (https=) |
| BR (1) | BR112021018036A2 (https=) |
| CA (1) | CA3133260A1 (https=) |
| EA (1) | EA202192497A1 (https=) |
| IL (1) | IL285822A (https=) |
| WO (1) | WO2020186216A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022216848A1 (en) * | 2021-04-06 | 2022-10-13 | Hemoshear Therapeutics, Inc. | Methods of treating methylmalonic acidemia and propionic acidemia |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1249706B (it) * | 1991-09-18 | 1995-03-09 | Sigma Tau Ind Farmaceuti | Uso di l-carnitina nella gravidanza a rischio. |
| AU3889197A (en) * | 1996-07-26 | 1998-02-20 | Douglas V Faller | Compositions comprising an inducing agent and an anti-viral agent for the treat ment of blood, viral and cellular disorders |
| US20050027006A1 (en) * | 2003-07-28 | 2005-02-03 | Reuben Matalon | Methods and materials for treating conditions associated with metabolic disorders |
| WO2011072086A1 (en) * | 2009-12-08 | 2011-06-16 | Hemaquest Pharmaceuticals, Inc. | Methods and low dose regimens for treating red blood cell disorders |
| US20120289476A1 (en) * | 2009-12-11 | 2012-11-15 | Jay Allan Barth | Methods for treating methylmalonic acidemia |
| US9018176B2 (en) * | 2010-12-02 | 2015-04-28 | Susan Perrine | Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders |
| ES2795798T3 (es) * | 2011-07-06 | 2020-11-24 | Ptc Therapeutics Inc | Tratamiento de aciduria metilmalónica, aciduria isovalérica, y otras acidurias orgánicas con tocotrienol quinonas |
| EP2877444B1 (en) * | 2012-07-27 | 2020-09-02 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| US20180064154A9 (en) * | 2015-09-01 | 2018-03-08 | D. Holmes Morton | Management of propionate metabolism disorders |
| JO3543B1 (ar) * | 2015-09-28 | 2020-07-05 | Applied Pharma Res | تراكيب حمض أميني إصدار معدل تعطى عن طريق الفم |
| WO2017139697A1 (en) * | 2016-02-10 | 2017-08-17 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with hyperammonemia |
| WO2017184583A1 (en) * | 2016-04-19 | 2017-10-26 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Anaplerotic agents for treatment of disorders of propionate and long chain fat metabolism |
-
2020
- 2020-03-13 EP EP20770425.5A patent/EP3937922A4/en not_active Withdrawn
- 2020-03-13 WO PCT/US2020/022760 patent/WO2020186216A1/en not_active Ceased
- 2020-03-13 AU AU2020236023A patent/AU2020236023A1/en not_active Abandoned
- 2020-03-13 KR KR1020217029827A patent/KR20210139274A/ko not_active Ceased
- 2020-03-13 JP JP2021555384A patent/JP2022525339A/ja active Pending
- 2020-03-13 BR BR112021018036A patent/BR112021018036A2/pt not_active Application Discontinuation
- 2020-03-13 EA EA202192497A patent/EA202192497A1/ru unknown
- 2020-03-13 CA CA3133260A patent/CA3133260A1/en active Pending
- 2020-03-13 US US17/438,560 patent/US20220142955A1/en not_active Abandoned
- 2020-03-13 CN CN202080020521.7A patent/CN113557014A/zh active Pending
-
2021
- 2021-08-24 IL IL285822A patent/IL285822A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL285822A (en) | 2021-10-31 |
| EP3937922A4 (en) | 2022-11-30 |
| CA3133260A1 (en) | 2020-09-17 |
| EP3937922A1 (en) | 2022-01-19 |
| JP2022525339A (ja) | 2022-05-12 |
| US20220142955A1 (en) | 2022-05-12 |
| WO2020186216A1 (en) | 2020-09-17 |
| CN113557014A (zh) | 2021-10-26 |
| KR20210139274A (ko) | 2021-11-22 |
| EA202192497A1 (ru) | 2021-11-18 |
| AU2020236023A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009056A (es) | Inhibidores de integrina ?v?6. | |
| CL2018000429A1 (es) | Moduladores de la expresión de kras | |
| BR112017011900A2 (pt) | tratamento de ataques com fosfatase alcalina recombinante | |
| CL2015002556A1 (es) | Inhibidores de la ruta de quinurenina | |
| MX2016016364A (es) | Terapia de combinacion con inhibidores de glutaminasa. | |
| ECSP21053104A (es) | Moduladores de la expresión de hsd17b13 | |
| EA201500996A1 (ru) | Терапевтические применения эмпаглифлозина | |
| JOP20210050A1 (ar) | معدلات تعبير pnpla3 | |
| EA201691320A1 (ru) | Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов | |
| EA201591278A1 (ru) | Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы | |
| EA201691155A1 (ru) | Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств | |
| PH12019502174A1 (en) | Modulators of pcsk9 expression | |
| MX374749B (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer. | |
| EA201591543A1 (ru) | Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki | |
| BR112019001398A2 (pt) | métodos para tratamento de câncer de próstata | |
| EA202092748A1 (ru) | Модуляторы экспрессии apol1 | |
| BR112022010686A2 (pt) | Mini-traps de vegf e métodos de uso dos mesmos | |
| EA201792124A1 (ru) | Биотин для лечения амиотрофического латерального склероза | |
| MX2021008865A (es) | Inhibidores de magl para usarse para tratar enfermedades antecedentes. | |
| PH12018502318A1 (en) | Compositions and methods for treatment of inflammation of infection of the eye | |
| BR112021018036A2 (pt) | Métodos de tratamento de acidemias orgânicas | |
| BR112021018611A2 (pt) | Anticorpos tendo especificidade para btn2 e usos dos mesmos | |
| EA202090266A1 (ru) | Ингибиторы mpo для применения в медицине | |
| MA55467A (fr) | Utilisations thérapeutiques de dulaglutide | |
| BR112014026813A2 (pt) | espaçadores de implante mamário para o tratamento de infecções de implante mamário periprostético |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |